A scientist at the Gladstone Institutes has discovered a novel way to convert human skin cells into brain cells, advancing medicine and human health by offering new hope for regenerative medicine and personalized drug discovery and development.
The Gladstone Institutes has been named America's best place to work in academia, capping a seven-year stint in which readers of The Scientist have ranked the independent biomedical-research organization among academia's top ten places to work.
The United States' National Academy of Sciences today elected Gladstone Senior Investigator Shinya Yamanaka MD, PhD, to its membership, bestowing yet another honor on the Japanese scientist whose discovery of a promising new stem-cell technology has major implications for human health.
A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.
The Massachusetts General Hospital (MGH) announced today that Shinya Yamanaka, MD, PhD, will receive the 2011 Warren Triennial Prize. Dr. Yamanaka discovered a method to convert adult cells into cells with characteristics of embryonic stem cells. He is on the faculty of both the Gladstone Institutes in San Francisco and Kyoto University in Japan. He will share the award with Rudolph Jaenisch, MD, of the Whitehead Institute and Massachusetts Institute of Technology. Dr. Jaenisch extended Dr. Yamanaka's work to generate animal models of important human diseases. The award will be presented at a daylong symposium in October 2011, part of the celebration of the 200th anniversary of the founding of the MGH.
Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) have found a new way to make beating heart cells from the body's own cells that could help regenerate damaged hearts. Over 5 million Americans suffer from heart failure because the heart has virtually no ability to repair itself after a heart attack. Only 2,000 hearts become available for heart transplant annually in the United States, leaving limited therapeutic options for the remaining millions. In research published in the current issue of Cell, scientists in the laboratory of GICD director Deepak Srivastava, MD, directly reprogrammed structural cells called fibroblasts in the heart to become beating heart cells called cardiomyocytes. In doing so, they also found the first evidence that unrelated adult cells can be reprogrammed from one cell type to another without having to go all the way back to a stem cell state.
Shinya Yamanaka, MD, PhD, of the Gladstone Institute of Cardiovascular Disease (GICD) and Kyoto University, has won the 2010 Kyoto Prize for Advanced Technology. Yamanaka, who is the L.K.Whittier Investigator in Stem Cell Biology at Gladstone, and professor of anatomy at UCSF, was cited for his discovery of a method of reprogramming adult skin cells to become embryonic-like stem cells. The discovery has opened up the field of stem cell research and dramatically changed the field of cell biology.
Shinya Yamanaka, MD, PhD, of the Gladstone Institute of Cardiovascular Disease (GICD) was awarded the 2010 March of Dimes Prize in Developmental Biology. Yamanaka, who is also a professor at Kyoto University, Japan, will be honored for his pioneering work that has fundamentally altered the field of developmental biology and will aid research into the prevention of birth defects.
Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.
The National Institutes of Health (NIH) has awarded a “Grand Opportunity” grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease(GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease and to develop potential therapies. The consortium comprises a partnership of five leading Huntington's research laboratories at the University of Wisconsin, Massachusetts General Hospital, the University of California at Irvine, Johns Hopkins and the Gladstone Institutes. The consortium will use induced pluripotent stem (iPS) cell technology pioneered by Gladstone and Kyoto University's Shinya Yamanaka, MD, PhD, to develop human neurons with Huntingtonís disease characteristics. iPS technology enables stem cells to be generated from skin samples from adults and avoids the ethical issues surrounding the use of fetal stem cells.